Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502455 | 0.97 | — | — | |
| SCHEMBL300758 | 0.97 | — | — | |
| SCHEMBL31292048 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL29426998 | 0.95 | — | — | |
| Bromide SCHEMBL379980 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL7950735 | 0.95 | — | — | |
| Methane SCHEMBL15323400 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL467422 | 0.95 | — | — | |
| Iodide SCHEMBL460164 | 0.95 | — | — | |
| Iodide SCHEMBL123176 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-07 | — | — | US | disclosed |
| EP-3892622-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023229346-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | 주식회사 체크메이트테라퓨틱스 | 2023-11-30 | — | — | WO | disclosed |
| US-20220017528-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-20 | — | — | US | disclosed |
| EP-3892622-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2021-10-13 | — | — | EP | disclosed |
| CN-111601803-A | Preparation method of tubulysin and intermediate thereof | 西雅图基因公司 | 2020-08-28 | — | — | CN | disclosed |
| WO-2020116972-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |
| WO-2020054657-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | 科研製薬株式会社 | 2020-03-19 | — | — | WO | disclosed |
| WO-2020054670-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | 科研製薬株式会社 | 2020-03-19 | — | — | WO | disclosed |
| CN-110461828-A | IP6K inhibitor | TAKEDA PHARMACEUTICALS CO | 2019-11-15 | — | — | CN | disclosed |
| CN-106536508-B | For treat Alzheimer disease have the active compound of cholinergic muscarinic M1 receptor positive allosteric regulator | 武田药品工业株式会社 | 2019-08-09 | — | — | CN | disclosed |
| CN-108431004-A | Heterocyclic compounds | 武田药品工业株式会社 | 2018-08-21 | — | — | CN | disclosed |
| CN-108026088-A | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2018-05-11 | — | — | CN | disclosed |
| CN-105612158-B | The somatostatin receptor hypotype 5 (SSTR5) antagonist | 武田药品工业株式会社 | 2017-06-30 | — | — | CN | disclosed |
| CN-106536508-A | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | 武田药品工业株式会社 | 2017-03-22 | — | — | CN | disclosed |
| CN-101267840-B | Antitumor bioconjugates of hyaluronic acid or derivatives thereof obtained by indirect chemical conjugation | FIDIA FARMACEUTICI | 2015-07-08 | — | — | CN | disclosed |